Literature DB >> 27457195

Detection of Activation Antigens on Chronic Lymphocytic Leukaemia Cells.

K Pálóczi1, É Pócsik1, R Mihalik1, M Benczur1, J Demeter1, V Solti1, G Petrányi1, S R Hollan1.   

Abstract

The peripheral blood mononuclear cells of patients with chronic lymphocytic leukaemia were characterized by the presence of a variety of cell surface differentiation antigens. The cells of 20 patients were found to be of B-cell phenotype when studied with antibodies directed against CD19, CD20, HLA-DR and sIg. Furthermore, a significant percentage of the cells gave a positive reaction with the monoclonal antibody to CD5. On the other hand, the CLL-cells did not express the CD21 antigen (C3d receptor, EBV receptor). We studied in parallel the presence of various activation antigens using 19 monoclonal antibodies grouped into 7 clusters (CD25, CD30, CD40, CD69, CD70, CD39, CD71). A significantly higher percentage of the CLL cells expressed activation antigens than lymphocytes from healthy controls. The percentage of CD3/HLA + DR + cells, compared to the healthy control lymphocytes was not increased in the CLL patients, and the activated cells in CLL were found to have characteristics of B-cells. Based on these results, we suggest that the CLL cells, like the cells in Hodgkin's disease and T-cell lymphoma, are not resting, but activated B-cells or the neoplastic abberrants of activated cells.

Entities:  

Keywords:  Activation antigens; CLL

Year:  1990        PMID: 27457195     DOI: 10.3109/10428199009050972

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Prognostic significance of the heterogenous expression of IgG Fc receptors in B-cell chronic lymphocytic leukemia.

Authors:  V Schranz; F Gráf
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

Review 2.  The CD70-CD27 axis in oncology: the new kids on the block.

Authors:  Tal Flieswasser; Astrid Van den Eynde; Jonas Van Audenaerde; Jorrit De Waele; Filip Lardon; Carsten Riether; Hans de Haard; Evelien Smits; Patrick Pauwels; Julie Jacobs
Journal:  J Exp Clin Cancer Res       Date:  2022-01-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.